Structural biology is a field dedicated to determining the three-dimensional structures of biomolecules, such as proteins, nucleic acids, and their complexes. By elucidating the spatial arrangements of these macromolecules, structural biology provides critical insights into their function, dynamics, and interactions with potential therapeutic compounds. This level of understanding is essential for guiding drug discovery and optimizing the efficacy of small-molecule inhibitors, biologics, and other therapeutic modalities.
One of the primary applications of structural biology in biopharma is in characterizing protein–ligand interactions, which underlie the mechanism of action for many drugs. By resolving atomic-level details of binding sites, researchers can design compounds with improved selectivity and potency, minimizing off-target effects and enhancing therapeutic outcomes. Structure-based drug design (SBDD) leverages these insights to rationally develop new drugs, an approach that has been instrumental in the development of kinase inhibitors, antiviral agents, and monoclonal antibodies (mAbs). Advances in structural biology techniques have also expanded beyond small molecule therapeutics to influence vaccine design, protein engineering, and gene therapy, making it a foundational discipline in modern biopharmaceutical research and development.
Historical Foundations of Structural Biology in Biopharma
The field of structural biology has evolved rapidly, driven by breakthroughs in experimental and computational techniques. These advancements have enabled scientists to decipher the atomic structures of biomolecules, paving the way for transformative drug discovery approaches. The development of X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy (cryo-EM) has provided increasingly detailed views of molecular interactions, allowing researchers to design therapeutics with unprecedented precision.
One of the earliest and most influential advancements in structural biology was the introduction of X-ray crystallography. The technique, pioneered in the early 20th century, became a cornerstone of biomolecular research following the first high-resolution protein structure determinations in the 1950s. The structures of myoglobin and hemoglobin, solved by John Kendrew and Max Perutz, respectively, demonstrated the power of crystallographic methods in elucidating protein architecture. These studies laid the foundation for future applications in biopharma, as understanding protein structure became essential for rational drug design.1 X-ray crystallography remains the gold standard for high-resolution structural determination of proteins and their interactions with ligands. By diffracting X-rays through crystallized biomolecules, researchers can generate electron density maps that reveal atomic-level details of protein conformations. This technique has played a pivotal role in structure-guided drug discovery, particularly in the development of HIV protease inhibitors, kinase inhibitors, and targeted cancer therapies.
As structural biology matured, NMR spectroscopy emerged as a complementary technique, particularly for studying smaller biomolecules and flexible protein regions. Unlike crystallography, NMR does not require the formation of protein crystals, allowing researchers to examine biomolecular dynamics in solution. This capability has been instrumental in studying intrinsically disordered proteins, allosteric interactions, and small molecule binding, expanding the range of structural insights applicable to drug discovery. The ability to capture conformational changes in solution has been critical for understanding allosteric regulation and transient binding interactions, both of which play key roles in drug efficacy. NMR has also facilitated fragment-based drug discovery, wherein small molecular fragments are screened for weak interactions with a target protein before being optimized into potent inhibitors. This approach has been successfully applied in the design of BCL-2 family protein inhibitors for cancer therapy.
More recently, cryo-EM has revolutionized structural biology by overcoming some of the limitations associated with crystallography and NMR. With the advent of direct electron detectors and advanced image-processing algorithms, cryo-EM has made it possible to resolve large, complex biomolecular assemblies at near-atomic resolution. This technique has been particularly impactful in the study of membrane proteins, viral structures, and large protein complexes, many of which were previously intractable by other methods.2 The ability to visualize molecular machines, such as ribosomes and ion channels, has led to new drug development opportunities targeting these critical biomolecules. Cryo-EM has also transformed antiviral drug discovery, as structural insights into viral glycoproteins and polymerases have informed the design of novel therapeutics. The characterization of SARS-CoV-2 spike protein structures using cryo-EM exemplifies its impact on vaccine development and antiviral drug screening.3
Beyond these technological milestones, structural biology has played a defining role in mapping enzymes and receptors that serve as key drug targets. By revealing the active sites and binding pockets of proteins, these structural studies have enabled the rational design of inhibitors and modulators for conditions ranging from cancer to infectious diseases. Molecular modeling and docking simulations have further refined the ability to predict drug–target interactions, accelerating lead compound optimization and reducing reliance on trial-and-error approaches in drug discovery.4
Computational methods have become indispensable tools in drug discovery, expanding the scope of structural biology applications. Molecular dynamics simulations allow researchers to model how proteins and ligands interact over time, capturing conformational changes that influence drug binding and efficacy.5 Advances in AI-driven structure prediction, exemplified by AlphaFold, have accelerated the modeling of previously unresolved protein structures, reducing the time and cost associated with experimental structure determination.6 These developments have been integrated into drug development pipelines, enabling structure-based virtual screening, de novo drug design, and optimization of lead compounds.
In silico screening and virtual docking strategies have also streamlined early-stage drug discovery. By computationally predicting how small molecules interact with target proteins, researchers can efficiently prioritize compounds for experimental validation. This approach, combined with high-throughput screening, has significantly improved the efficiency of lead identification.7
As structural biology techniques continue to evolve, their applications in drug discovery are becoming increasingly sophisticated. The integration of experimental methods with computational modeling is enabling a more comprehensive understanding of biomolecular function, ultimately leading to the development of more effective and precisely targeted therapeutics.
Applications of Structural Biology in Biopharmaceutical Development
Structural biology plays a crucial role in the development of biopharmaceuticals, providing atomic-level insights that drive the design and optimization of therapeutic molecules. Its applications extend beyond small molecule drug discovery to encompass biologics, vaccines, gene and cell therapies, and novel therapeutic modalities. By leveraging structural data, researchers can enhance drug efficacy, improve selectivity, and develop new strategies for treating complex diseases.
SBDD is one of the most direct applications of structural biology in biopharmaceutical development. By resolving high-resolution structures of drug targets, researchers can rationally design compounds that precisely fit into binding pockets, leading to more potent and selective therapeutics. Structural insights are particularly valuable in optimizing lead compounds by improving their binding affinity and pharmacokinetics. A key example is the development of kinase inhibitors in oncology, where structural characterization of kinase domains has facilitated the design of highly specific inhibitors. The success of tyrosine kinase inhibitors, such as imatinib and Osimertinib, illustrates how structural biology has transformed targeted cancer therapies.4
mAb development and protein engineering have also benefited significantly from structural biology. Antibody–drug conjugates (ADCs), which link mAbs to cytotoxic agents, rely on precise structural optimization to ensure selective delivery of therapeutic payloads. By analyzing the structure of antigen–antibody interactions, researchers can engineer biologics with enhanced binding affinity, stability, and reduced immunogenicity.8 Additionally, structural studies guide the development of next-generation biologics, such as bispecific antibodies and Fc-engineered proteins, expanding the therapeutic potential of biologics.
Vaccine development has been revolutionized by structural biology, particularly in the rational design of immunogens. The determination of viral protein structures, such as the SARS-CoV-2 spike protein, has enabled the design of vaccines with optimized antigen presentation. Structural insights help identify key epitopes that elicit robust immune responses, guiding the selection of stabilizing mutations that enhance vaccine efficacy. The application of cryo-EM in characterizing viral glycoproteins has played a crucial role in developing mRNA-based vaccines and subunit vaccines. Furthermore, structural biology has informed the design of broadly neutralizing antibodies and next-generation vaccines targeting evolving viral strains.
Allosteric modulators represent an emerging class of therapeutics that leverage structural biology to target regulatory sites on proteins rather than traditional active sites. Allosteric drugs offer advantages in selectivity and reduced off-target effects, as they can modulate protein function without directly competing with endogenous ligands. Structural studies have elucidated how small molecules can induce conformational changes that alter protein activity, paving the way for new therapeutic strategies. Structure-guided approaches have been instrumental in designing small-molecule modulators for ion channels, G protein–coupled receptors (GPCRs), and transcription factors.
Gene and cell therapy innovations have also been shaped by structural biology, particularly in vector design and genome editing. Understanding the structures of viral capsids has facilitated the engineering of adeno-associated virus (AAV) vectors with improved transduction efficiency and tissue specificity. Structural studies of CRISPR-Cas9 and related genome-editing enzymes have provided insights into their DNA-binding mechanisms, allowing for the development of more precise and efficient gene-editing tools. Additionally, structural biology has contributed to optimizing the stability and packaging of mRNA therapeutics, further advancing the field of genetic medicine.
From targeted drug discovery to cutting-edge biopharmaceutical innovations, structural biology continues to expand the frontiers of therapeutic development. By integrating structural insights with computational modeling and experimental validation, researchers are accelerating the design of safer, more effective treatments across a wide range of diseases.
Evolving Technologies and Trends in Structural Biology for Biopharma
The landscape of structural biology is continually evolving, driven by technological advancements that expand the resolution, speed, and predictive capabilities of molecular studies. Emerging techniques and computational tools are enhancing drug discovery, accelerating biopharmaceutical development, and offering new possibilities for precision medicine. Innovations in cryo-EM, AI, high-throughput screening, quantum mechanics modeling, and systems biology are shaping the future of the field.
Next-generation cryo-EM and single-particle analysis are pushing the boundaries of structural resolution and real-time molecular visualization. Advances in detector technology, image-processing algorithms, and sample preparation methods have improved the ability to capture biomolecular structures at near-atomic resolution. These developments enable researchers to study proteins in their native conformational states, providing a deeper understanding of structural dynamics and transient interactions. The ability to visualize large molecular machines, such as ribosomes and membrane proteins, with unprecedented clarity has led to novel therapeutic targets and the refinement of drug candidates.
The integration of structural biology with AI and machine learning is transforming how protein–ligand interactions are predicted and analyzed. AI-driven methods allow for rapid protein structure prediction, virtual screening, and de novo drug design. Predictive modeling techniques facilitate the identification of promising drug candidates before experimental validation, significantly reducing the time and cost associated with drug development. Generative AI is being applied to design novel molecular scaffolds with optimized pharmacological properties, expanding the chemical space available for drug discovery.6 The widespread adoption of AI-driven approaches, including AlphaFold and Rosetta, has already demonstrated their value in refining protein models and accelerating structure-based drug design.
Microfluidics and high-throughput structural screening are improving the efficiency of experimental workflows in structural biology. Automated microfluidic platforms enable rapid sample preparation, crystallization, and data collection, making it possible to analyze thousands of conditions in parallel. This technology has been particularly impactful in fragment-based drug discovery, where large libraries of small molecules are screened against a target protein to identify promising lead compounds. The ability to integrate microfluidics with cryo-EM and X-ray crystallography is streamlining the structural characterization of drug-target interactions.
Quantum mechanics / molecular mechanics (QM/MM) hybrid methods are advancing computational chemistry in drug development. These techniques combine quantum mechanical precision with molecular mechanics simulations to model complex biomolecular interactions at an atomic level. QM/MM methods are particularly valuable in studying enzymatic reactions, metal-containing proteins, and non-covalent interactions that are critical for drug binding. By refining the accuracy of molecular simulations, these approaches are providing deeper insights into the energetics and specificity of drug–target interactions.
Structural proteomics and systems biology are expanding the applications of structural biology beyond individual biomolecules to entire cellular networks. Mapping the interactome — comprehensive protein–protein and protein–ligand interaction networks — is helping researchers identify novel disease pathways and therapeutic targets. High-throughput proteomics techniques, combined with computational modeling, allow for the reconstruction of cellular signaling pathways, enhancing the understanding of disease mechanisms and drug response.9 Structural biology’s role in systems pharmacology is becoming increasingly important for personalized medicine, as it enables the rational design of therapies tailored to individual molecular profiles.
As these technologies continue to mature, they are expected to further accelerate the pace of discovery in biopharma. The convergence of structural biology with AI, high-throughput automation, and computational modeling is enabling more precise and efficient drug development strategies. These innovations are not only improving the success rates of drug candidates but also driving new therapeutic possibilities across a broad spectrum of diseases.
The Future Impacts of Structural Biology
As structural biology continues to evolve, its integration with emerging fields such as precision medicine, biologics, and sustainable drug discovery is shaping the future of biopharmaceutical innovation. Advancements in high-resolution structural techniques, AI, and systems biology are expanding the scope of molecular characterization, enabling more targeted and efficient drug development strategies. The future of structural biology in biopharma lies in bridging the gap between structure-based insights and real-world clinical applications, advancing biologic and genetic therapies, and increasing accessibility to structural data.
Bridging the gap between structural biology and personalized medicine is a critical area of future development. Structural biomarkers, which provide molecular signatures of disease at the atomic level, are expected to play an increasingly important role in precision drug development. By characterizing the unique structural variations in proteins associated with disease states, researchers can tailor treatments to specific patient populations. Advances in cryo-EM and AI-driven modeling are making it possible to predict individual protein conformations and how they interact with therapeutic agents. These insights will enable more personalized approaches to drug design, reducing the risks of adverse effects and improving treatment efficacy.
Expanding structural biology’s role in biologics and advanced therapies will further transform the pharmaceutical landscape. Protein engineering is already being used to develop next-generation therapeutic proteins, including mAbs, ADCs, and bispecific antibodies. Structural insights into protein folding, binding, and stability are essential for optimizing these therapies, improving their half-life, and reducing immunogenicity. Additionally, RNA-based therapeutics, including mRNA vaccines and small interfering RNA (siRNA) therapies, are benefiting from structural characterization that guides sequence design, secondary structure optimization, and delivery mechanisms. Structural biology is also contributing to the development of more stable and efficient viral vectors for gene and cell therapies, enabling precise genome editing and long-term therapeutic effects.
Sustainability and accessibility in structural biology are growing concerns as the field continues to expand. Cost-effective approaches to structure determination are essential for democratizing access to high-resolution molecular data. While cryo-EM, X-ray crystallography, and NMR spectroscopy remain expensive and resource-intensive, innovations in computational modeling and AI-driven predictions are helping to bridge the gap. Open-access structural databases, improved automation in data collection, and collaborative global initiatives are making structural biology tools more widely available to researchers in both academia and industry. Ensuring that these resources are accessible will be critical for fostering innovation in drug discovery, particularly in low- and middle-income countries.
The continued evolution of structural biology is expected to accelerate the development of new therapeutics across a broad range of diseases. By integrating experimental techniques with computational modeling and AI, researchers can refine drug discovery pipelines, improve biologic engineering, and develop more precise, efficient, and accessible treatments. As structural biology becomes more deeply embedded in personalized medicine and advanced therapeutic development, its role in biopharma will only continue to expand.
References
Congreve M, CW Murray, and TL Blundell. “Key insights into drug discovery from structure-based design.” Drug Discovery Today. 10: 895-907 (2005).
Burley SK, A Wu-Wu, S Dutta, et al. “Impact of structural biology and the protein data bank on U.S. FDA new drug approvals of low molecular weight antineoplastic agents." Oncogene. 43: 2229–2243 (2024).
Schwalbe H, P Audergon, N Haley, et al. “The future of integrated structural biology.” Structure. 32: P1563–1580 (2024).
Du, G, S Rao, et al. “Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.” J. Med. Chem. 63: 1624-1641 (2024).
Roversi P, G Molla and M Nardini. “Editorial: Integration of structural biology data in lead drug discovery and optimization.” Front. Mol. Biosci. 31 Jan. 2023.
Cebi E, J Lee, VK Subramani, et al. “Cryo-electron microscopy-based drug design.” Front. Mol. Biosci. 3 Mar. 2024.
Blundell, TL, BL Sibanda, RW Montalvao, et al. “Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery.” Philos. Trans. R. Soc. Lond. B. Bio. Sci. 361:413-423 (2006).
“Structural Biology Market Experiencing Rapid Growth.” BioSpace. 15 Apr. 2024.
“Structural Biology Services.” Charles River Laboratories. Accessed 27 Feb. 2024.